Free Trial

Pacira BioSciences Q1 2023 Earnings Report

Pacira BioSciences logo
$24.91 -0.39 (-1.54%)
As of 03/28/2025 04:00 PM Eastern

Pacira BioSciences EPS Results

Actual EPS
$0.32
Consensus EPS
$0.40
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Pacira BioSciences Revenue Results

Actual Revenue
$160.34 million
Expected Revenue
$157.02 million
Beat/Miss
Beat by +$3.32 million
YoY Revenue Growth
N/A

Pacira BioSciences Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Pacira BioSciences Earnings Headlines

What is Zacks Research's Forecast for PCRX FY2027 Earnings?
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Pacira BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email.

About Pacira BioSciences

Pacira BioSciences (NASDAQ:PCRX) is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

View Pacira BioSciences Profile

More Earnings Resources from MarketBeat